-
ABT-263 (Navitoclax): Translational Apoptosis Strategy
2026-09-21
ABT-263 (Navitoclax) is more than a Bcl-2 family inhibitor: it is a mechanistic probe for determining how mitochondrial apoptotic priming, anti-apoptotic protein dependence, and treatment resistance interact. This thought-leadership guide translates BH3-mimetic biology into practical strategies for cancer models, apoptosis assays, and translational study design.
-
Verapamil HCl: Calcium Signaling Workflows
2026-09-20
Learn how to use Verapamil HCl as both an L-type calcium channel blocker and a mechanistic probe in myeloma, apoptosis, transporter, and arthritis inflammation studies. The workflow emphasizes formulation control, orthogonal readouts, and safeguards against confusing calcium-channel effects with altered intracellular drug accumulation.
-
A40926: From Biosynthesis to Assay Insight
2026-09-19
A40926 is more than a dalbavancin precursor: its biosynthetic regulation explains how production context can strengthen antibacterial research. This article connects pathway engineering, mechanism, MIC interpretation, and translational study design in one evidence-based framework.
-
GDC-0941: PI3K Inhibitor Mechanism and Workflows
2026-09-18
GDC-0941 is an orally bioavailable PI3K inhibitor that blocks class I PI3K signaling through ATP-site competition and suppresses PIP3-dependent Akt activation. Product-dossier benchmarks support pathway inhibition in cancer-cell assays and tumor-growth reduction in an oral xenograft study, while the DRD4–Akt–β-catenin liver-cancer evidence provides biological rationale rather than direct proof of GDC-0941 efficacy.
-
p-Tau Ser356, NUAK1, and Alzheimer’s Pathology
2026-09-18
This study links tau phosphorylation at Ser356 to advancing Alzheimer’s disease pathology, neurofibrillary tangles, and synaptic localization, then tests NUAK inhibition in mouse and human brain slice cultures. WZ4003 lowered p-tau Ser356 in adult human slices, while mouse cultures showed broader, culture-phase-dependent protein loss, highlighting the importance of model selection in tau-targeted research.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-17
The reference study identifies CD44-driven metabolic rewiring as a dependency of IDH-mutant leukemia, linking pentose phosphate pathway activity and NADPH production to sustained R-2HG synthesis. Its isogenic genetic models and combination experiments suggest that CD44 blockade could complement mutant-IDH inhibition, while also providing a mechanistic framework for studying resistance.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-17
The reference study identifies CD44 as a metabolic dependency in IDH-mutant leukemia, linking altered glucose handling to NADPH production and sustained R-2HG synthesis. Its isogenic CRISPR-based design supports combined targeting of mutant IDH activity and CD44-mediated metabolic rewiring as a strategy for investigating resistance in AML.
-
KX2-391 as an Inhibitor of HBV Transcription
2026-09-16
Harada and colleagues used a recombinant HBV carrying a NanoLuc reporter to screen 1,827 FDA-approved compounds and identify KX2-391 as a suppressor of HBV infection. Their mechanistic experiments indicate that the antiviral effect is linked primarily to inhibition of tubulin polymerization and HBV precore-promoter activity, rather than to Src kinase inhibition.
-
WY-14643: PPARα Signaling for Translational Research
2026-09-16
WY-14643 (Pirinixic Acid) is more than a lipid-metabolism tool: it offers a tractable way to connect PPARα activation with inflammation, insulin sensitivity, liver growth, and regenerative signaling. This thought-leadership guide translates mechanistic evidence into a rigorous strategy for metabolic and liver research.
-
Estradiol Benzoate: From ERα Binding to Translation
2026-09-15
A translational framework for using Estradiol Benzoate to connect ERα binding, estrogen receptor-mediated signaling, assay quality, and cross-species interpretation without overstating preclinical evidence.
-
DNP-Induced seRNA Drives NPC Metastasis
2026-09-15
The 2023 reference study identifies a carcinogen-responsive super-enhancer RNA, seRNA-NPCm, as a functional regulator of nasopharyngeal carcinoma metastasis. Integrating transcriptomic, nascent-transcription, chromatin, perturbation, and patient-tissue analyses, the authors connect seRNA-NPCm to an NPM1/c-Myc/NDRG1 regulatory axis and provide a framework for studying enhancer-associated RNA in carcinogen-driven disease.
-
Polyphyllin H and Paclitaxel Resistance
2026-09-14
A 2025 study identifies membrane cholesterol and lipid rafts as a tractable vulnerability in paclitaxel-resistant breast cancer. Its data indicate that Polyphyllin H can reduce ABCB1- and ABCC3-mediated drug efflux, increase intracellular paclitaxel, and restore treatment response more effectively than lovastatin in the tested models.
-
RIPA Lysis Buffer (Medium) for EV Signaling
2026-09-14
Translate extracellular-vesicle stimulation into reproducible cell and tissue lysates for pathway-focused Western blots, immunoprecipitation, and complementary protein assays. RIPA Lysis Buffer (Medium) combines broad membrane disruption with built-in protection against proteolysis and dephosphorylation, while its limitations make assay-specific optimization essential.
-
FOXO3/YAP Dual Metabolic Targeting in HCC
2026-09-13
This 2026 Oncogene study identifies FOXO3 as a transcriptional suppressor of YAP-driven glycolysis and glutaminolysis in hepatocellular carcinoma. By combining cellular, animal, and patient-derived organoid models, the work supports coordinated metabolic inhibition as a strategy that may overcome compensation between glucose and glutamine metabolism.
-
BRD4 Inhibition Sensitizes Cells to Erastin Ferroptosis
2026-09-12
Fan et al. show that pharmacological or genetic BRD4 inhibition broadly increases erastin-induced ferroptosis across several cell lines. The study identifies reactive oxygen species accumulation and suppression of the ferroptosis defense factor FSP1 as key mechanistic links, supporting combination strategies that pair BET inhibition with ferroptosis induction.